cardiometabolic

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity PipelineiBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as…

2 weeks ago
ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing RegimenACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen

ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen

LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious…

2 months ago